BofA analyst Joshua Dennerlein upgraded Healthpeak Properties to Buy from Underperform with a price target of $25, up from $18. The firm thinks the market is mis-prising Healthpeak’s go-forward growth prospects and thinks earnings will trough in 2024, the analyst tells investors in a research note. Additionally, BofA believes there is significant NOI upside from leasing up developments and redevelopments, with additional upside that can be driven by asset sales and stock buybacks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Healthpeak Properties price target raised to $26 from $22 at Baird
- Healthpeak Properties resumed with an Equal Weight at Wells Fargo
- Healthpeak Properties resumed with an Outperform at RBC Capital
- Healthpeak Properties price target lowered to $22 from $23 at Scotiabank
- Healthpeak Properties resumed with Neutral from Overweight at JPMorgan
